Chinese University Investigates Neuroscientist After Undisclosed Death of Girl, 6, in Brain-Directed Gene-Editing Trial

Overview

Shanghai Jiao Tong University has opened an investigation into one of its own neuroscientists after a six-year-old girl died from a severe immune reaction roughly a week after receiving an experimental, brain-directed gene-editing treatment, according to SCMP. The death, which took place in March 2025, was not disclosed publicly until a report surfaced this month, according to Medical Xpress.

What We Know

The girl, given the pseudonym “Mei,” had Snijders Blok-Campeau syndrome, a rare genetic condition that causes delayed cognitive development but is not life-threatening, according to Medical Xpress. The condition is caused by a single mutated DNA base in the gene now widely written as CHD3, according to Medical Xpress, and the therapy aimed to correct that mutation using a base-editing approach, a technique that alters individual DNA letters rather than cutting the genome, according to SCMP.

According to SCMP, the girl’s medical team infused trillions of viruses carrying the base editor into her spinal fluid at Xinhua Hospital, a facility affiliated with Shanghai Jiao Tong University. Seven days later, she died of a severe immune reaction linked to the therapy, SCMP reported, a timeline corroborated by Medical Xpress, which similarly reported that she “died a week later from a severe immune reaction.” Her parents paid more than $800,000 to fund the experimental treatment, according to Medical Xpress.

The lead researcher on the project, neuroscientist Zilong Qiu of Shanghai Jiao Tong University, is now under investigation by the university, which confirmed it is looking into the case, according to SCMP. Xinhua Hospital has already paid a fine of about 24,000 yuan (roughly $3,500) to local health authorities, SCMP reported.

Qiu’s related animal research on base editing of the same gene was published in Nature without any disclosure that a human trial, or a death, had occurred. That paper, titled “In vivo base editing of Chd3 rescues behavioural abnormalities in mice”, describes preclinical work in mice and nonhuman primates and states that the results “support the clinical applicability of this approach” — but its published text contains no reference to a clinical trial, a patient, or any adverse outcome. The paper also states that “bridging the gap between preclinical research and clinical translation remains a significant challenge,” according to Medical Xpress, which cited that line directly from the publication. Live Science reported that the case has raised broader questions about oversight of gene-therapy research in China, since the girl’s syndrome was not life-threatening.

What We Don’t Know

Neither SCMP nor Medical Xpress detailed what ethical review or regulatory approval process, if any, the trial went through before the treatment was administered, or what specific findings the university’s investigation has reached so far. It also remains unclear what consequences, if any, Qiu or Xinhua Hospital may face beyond the fine already issued, and whether the Nature paper will be corrected, retracted, or otherwise amended in light of the undisclosed trial.

Analysis

The case lands at the intersection of two separate scientific narratives: a legitimate, peer-reviewed advance in base-editing technology capable of correcting single-letter DNA mutations in the brain, and a largely unregulated path by which that technology reached a paying patient before its safety in humans had been established. The gap between what the Nature paper tells the scientific community — a promising proof of concept in mice and primates — and what a family says it experienced after paying more than $800,000 for an unproven treatment for a non-life-threatening condition is now the subject of Shanghai Jiao Tong University’s inquiry.